Healthcare Facilities & Services

Page 1

LifeWatch AG receives FDA 510(k) clearance for its Vital Signs Patch (VSP)

Monday, 22 Dec 2014 01:00am EST

LifeWatch AG:Receives FDA 510(k) clearance for its Vital Signs Patch (VSP).Expects to launch VSP in Q3 2015.

Summerset Group Holdings Ltd to build retirement village in Wigram

Tuesday, 2 Dec 2014 06:00pm EST

Summerset Group Holdings Ltd:Says that it has been granted resource consent to build a NZ$80 million retirement village in Wigram, Christchurch, which will see the company achieve a long-held goal.Says the village will be the company’s first in Christchurch, and will be Summerset’s 20th village nationwide.The company is working towards lodging resource consent for a village on that site, and is aiming to have homes available in the next few years.

Cancer Genetics Inc receives second patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT

Tuesday, 11 Nov 2014 07:55am EST

Cancer Genetics Inc:Announces that it has received a second US patent covering its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.

Summerset Group Holdings Ltd plans for NZ$55 million retirement village

Sunday, 19 Oct 2014 04:00pm EDT

Summerset Group Holdings Ltd:Says that it has released plans for its New Plymouth retirement village.Says the first 14 homes will be completed next month and residents are expected to move in before Christmas.

Enzo Biochem awarded patent for Novel Vectors involving Gene Therapy Treatments for cancer, virus infections and genetic diseases

Tuesday, 7 Oct 2014 09:00am EDT

Enzo Biochem Inc:Says U.S. Patent and Trademark Office has awarded company Patent No. 8,846,893, covering novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.

Trovagene Inc expands clinical program with new study evaluating its precision cancer monitoring platform in lung cancer

Monday, 29 Sep 2014 08:05am EDT

Trovagene Inc:Says it has expanded its clinical program to include a study designed to evaluate use of its precision cancer monitoring technology in the management of lung cancer patients.Says primary objective of the study is to detect and monitor EGFR mutations in urine, plasma and tissue to determine concordance.Says Secondary objectives include correlating quantitative EGFR mutational load over time with tumor burden, and demonstrating detection of the resistant EGFR T790M mutation prior to clinical or radiographic progression in lung cancer patients treated with tyrosine kinase inhibitor therapy.Says about 225 patients are anticipated to be enrolled in the study.

iMedicor Inc launches proprietary iCoreDental, Cloud-Based, customizable electronic health records platform

Tuesday, 5 Aug 2014 10:17am EDT

iMedicor Inc:Launches second cloud-based software product one week following the launch of iCoreMD.iCoreDental is a fully customizable, cloud-based, Electronic Heath Record (EHR) system for dentists.

CombiMatrix Corp 's Pediatric development disorders analysis test granted conditional approval from New York State Department of Health

Tuesday, 15 Jul 2014 08:00am EDT

CombiMatrix Corp:Says its chromosomal microarray analysis (CMA) test to identify development disorders in pediatric patients, the CombiSNP Array for Pediatric Analysis, has received conditional approval from the New York Department of Health for testing on patient samples.CMA testing for pediatric development disorders, such as its CombiSNP CMA test, is recommended by the American College of Medical Genetics for individuals with developmental delays, birth defects, physical deformities or autism or autism spectrum disorder.Under conditional approval, CombiMatrix will be able to market the test in New York while the test is under Clinical Laboratory Reference System review.Upon completion of the review, either the test will receive full marketing approval or additional information will be required in order to achieve final approval.

Signal Genetics Inc obtains New York State approval for MyPRS Multiple Myeloma Prognostic Test

Monday, 30 Jun 2014 08:30am EDT

Signal Genetics Inc:New York State Department of Health approval of its MyPRS (Myeloma Prognostic Risk Signature) test.MyPRS is a microarray-based gene expression profiling assay used to assist in treatment planning and disease management of patients with multiple myeloma and related disorders.By profiling genomes of patients' isolated plasma cells, MyPRS generates a personalized prognostic score and molecular subtype that may inform each patient's specific therapeutic alternatives.Extensive clinical trials and international peer-reviewed studies reinforce the clinical validity and utility and prognostic performance of the test.

Enzo Biochem receives U.S. patent on more efficient vector for use in gene therapy

Friday, 6 Jun 2014 08:30am EDT

Enzo Biochem Inc:Assigned U.S. Patent Office Patent No. 8,742,090, related to the construct of an artificial vector capable of greater efficiency, in general, in targeting specific cells in the application of gene therapy and gene transfer technology.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Market Edge
$10.00
Provider: Market Edge
$10.00
Provider: Auerbach Grayson & Co., Inc.
$25.00
Provider: Auerbach Grayson & Co., Inc.
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.